The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
This study was designed to determine the effects of vandetanib, a small-molecule receptor tyrosine kinase inhibitor of vascular endothelial growth factor and epidermal growth factor receptor, on paclitaxel (PTX) tumor distribution and antitumor activity in xenograft models of human ovarian carcinoma...
Κύριοι συγγραφείς: | Cesca, M, Frapolli, R, Berndt, A, Scarlato, V, Richter, P, Kosmehl, H, D'Incalci, M, Ryan, A, Giavazzi, R |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
2009
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
The Effects of Vandetanib on Paclitaxel Tumor Distribution and Antitumor Activity in a Xenograft Model of Human Ovarian Carcinoma
ανά: Marta Cesca, κ.ά.
Έκδοση: (2009-11-01) -
Hyaluronic Acid- Paclitaxel: Antitumor Efficacy against CD44(+) Human Ovarian Carcinoma Xenografts
ανά: Edmond Auzenne, κ.ά.
Έκδοση: (2007-06-01) -
Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
ανά: Wachsberger, P, κ.ά.
Έκδοση: (2009) -
Determination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imaging.
ανά: Lavinia Morosi, κ.ά.
Έκδοση: (2013-01-01) -
Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.
ανά: Choi, S, κ.ά.
Έκδοση: (2008)